Kelly Lawrence W & Associates Inc. CA Sells 3,232 Shares of Johnson & Johnson (NYSE:JNJ)

Kelly Lawrence W & Associates Inc. CA trimmed its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 59,121 shares of the company's stock after selling 3,232 shares during the quarter. Johnson & Johnson makes up about 2.0% of Kelly Lawrence W & Associates Inc. CA's investment portfolio, making the stock its 22nd largest holding. Kelly Lawrence W & Associates Inc. CA's holdings in Johnson & Johnson were worth $8,550,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Landing Point Financial Group LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $319,000. Mirabella Financial Services LLP bought a new stake in shares of Johnson & Johnson during the 4th quarter worth about $955,000. MetLife Investment Management LLC lifted its stake in shares of Johnson & Johnson by 1.8% in the 4th quarter. MetLife Investment Management LLC now owns 637,349 shares of the company's stock worth $92,173,000 after acquiring an additional 11,299 shares during the period. Natixis boosted its holdings in shares of Johnson & Johnson by 16.4% in the fourth quarter. Natixis now owns 165,510 shares of the company's stock valued at $23,936,000 after acquiring an additional 23,261 shares in the last quarter. Finally, Norinchukin Bank The increased its stake in shares of Johnson & Johnson by 7.4% during the fourth quarter. Norinchukin Bank The now owns 117,460 shares of the company's stock valued at $16,987,000 after acquiring an additional 8,049 shares during the period. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 6,999 shares of the business's stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the transaction, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.8 %

Johnson & Johnson stock traded down $1.21 during trading hours on Thursday, hitting $154.17. The company had a trading volume of 4,082,378 shares, compared to its average volume of 9,769,074. The firm's fifty day moving average is $159.52 and its 200-day moving average is $154.95. The firm has a market capitalization of $371.52 billion, a P/E ratio of 23.18, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $21.89 billion for the quarter, compared to the consensus estimate of $21.65 billion. On average, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th will be issued a $1.30 dividend. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a yield of 3.37%. The ex-dividend date is Tuesday, May 27th. Johnson & Johnson's payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Bank of America decreased their price target on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Stifel Nicolaus reduced their price objective on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $171.82.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.